Results 131 to 140 of about 15,238,642 (306)

In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application

Advanced Science, EarlyView.
This review examines the potential of in vivo direct reprogramming in regenerative medicine for functional tissue restoration, highlighting the role of tissue‐resident cues in generating functionally mature reprogrammed cells from lineage‐related cells. It contains a discussion on mechanisms, reprogramming factors, delivery approaches, and applications
Rishabh Deo Singh, Mauro Calvoli, Kyeong Kyu Kim   +2 more
wiley   +1 more source

Why CD4+ T cells matter in adoptive cell therapy for solid cancers

Immuno-Oncology and Technology
Cytotoxic CD8+ T cells have been the focus of research efforts to improve the efficacy of anticancer adoptive cell therapies. However, emerging evidence is highlighting the critical role of CD4+ T cells in these treatments, including chimeric antigen ...
S. Jegatheeson, C. Scheffler, M. De Bondt, P.K. Darcy, P.J. Neeson   +4 more
doaj   +1 more source

An Engineered HR1‐Stem Helix‐HR2 Trimeric Platform for Developing Broad‐Spectrum Coronavirus Vaccines

Advanced Science, EarlyView.
Sun et al. report a self‐assembling trimeric subunit vaccine platform termed RHS, which integrates the JN.1 receptor‐binding domain (RBD) with the heptad repeat 1 (HR1), stem helix (SH), and heptad repeat 2 (HR2) regions. The SARS‐CoV‐2 RHS vaccine elicits variant‐reactive RBD‐specific antibodies and cross‐reactive SH‐specific antibodies against ...
Xikui Sun, Junhao Fan, Xiaolu Xie, Yuting Shi, Xiaoqing Liu, Tiefeng Xu, Sidi Yang, Keda Shi, Chengshu Xie, Shixiong Li, Siwen Chen, Ruoxi Cai, Ping He, Yuzhen Ye, Tao Chen, Xiancai Ma, Chunmei Li, Jingyou Yu, Deyin Guo   +18 more
wiley   +1 more source

Structural Basis of Shiga Toxin Neutralization by Human Antibodies Targeting Canonical Receptor‐Binding and Non‐Canonical Assembly Sites

Advanced Science, EarlyView.
Cryo‐electron microscopy structures reveal two distinct neutralization mechanisms of fully human monoclonal antibodies targeting the Shiga toxin 1a B subunit. RDS059 occludes the Gb3 receptor‐binding site, whereas RDS045 engages a lateral quaternary epitope to disrupt holotoxin assembly.
Jianting Ke, Xin Li, Xiaoli Wang, Zhaoxia Huang, Shaojie Xue, Yuyang Liu, Jing Pan, Guowei Hu, Yayu Wang, Cheng Wang, Shoudeng Chen   +10 more
wiley   +1 more source

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

Advanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie, Jie Huang, Chunhao Cao, Zhenchao Tang, Xingchen Li, Jianmin Guo, Xinxin Chen, Fang Wang, Dongyi He, Jie Li, Yu Du, Bing He, Jianhua Yao, Aiping Lu, Chao Liang   +14 more
wiley   +1 more source

CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation

Advanced Science, EarlyView.
CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu, Zhou Jing Zhang, Jing Jin, Hai Yuan Xu, Ya Xin Gu, Qian Qian Yang, You Lang Zhou   +6 more
wiley   +1 more source

Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment

Frontiers in Immunology
Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies.
Riley Rane, Riley Rane, Fengqiao Li, Fengqiao Li, Alexis Williams, Alexis Williams, Avaneesh Jayadev, Avaneesh Jayadev, Nhan L. Tran, Nhan L. Tran, Jeffrey A. Winkles, Jeffrey A. Winkles, Gloria B. Kim, Gloria B. Kim   +13 more
doaj   +1 more source

Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers

Advanced Science, EarlyView.
AMT‐676 is a novel antibody‐drug conjugate targeting CDH17, an adhesion molecule uniquely exposed on gastrointestinal tumor surfaces. Engineered with an optimized exatecan payload, it demonstrates profound tumor regression and a robust bystander effect across diverse preclinical models.
Ying‐nan Wang, Dan‐yun Ruan, Jing Shi, Yue Huang, Hui Sheng, Ya‐ling Huang, Linjie Ma, Lijun Wang, Caiwei Chen, Yixuan Wang, Yue Zhang, Yi Shen, Qing Zhang, Jianjian Zhang, Yanfang Tang, Jin‐ling Zhang, Jia‐jia Hu, Chen‐yi Wu, Jia‐ying Chen, Xun Meng, Shu‐Hui Liu, Feng Wang   +21 more
wiley   +1 more source

Chimeric antigen receptor T-cell therapy

, 2019
Although treatment of haematological cancer has improved significantly during the latest decades, the prognosis is poor in case of relapse or refractory disease.
Met, Özcan, Kielsen, Katrine, Svane, Inge Marie, Müller, Klaus, Ifversen, Marianne, Petersen, Søren Lykke   +5 more
core   +1 more source

ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses.

, 2001
The enzyme-linked immunospot technique (ELISPOT) relies on the visualization of cytokine secretion by individual T cells following in vitro stimulation with antigen. This assay has been developed and standardized for the quantitative detection of antigen-
Luzia H Carvalho, Carvalho, LH, Fidel Zavala, Julius C.R Hafalla, Hafalla, JC, Zavala, F   +5 more
core   +1 more source